Floatz logo

MICAFUNGIN

Immunocompromised

Children's Hospital Medical Center, CincinnatiSmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Immunocompromised cohort.

Asset / SponsorPhaseRating
Busulphan
University of California, San Francisco
Phase 2BB
Evomela
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2BB
Thiotepa
University of California, San Francisco
Phase 2BB
Fludarabine
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2BB
HUMAN IMMUNOGLOBULINS
Grifols Therapeutics LLC
Phase 3B

View all 23 →

Same molecule, other indications

MICAFUNGIN is also rated in:

nutritional deficiency diseaseDormant
B
Indicative ·
61 / 100
View asset →
acute myeloid leukemiaDormant
B
Indicative ·
60 / 100
View asset →
morbid obesityDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →